De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset
Identifieur interne : 003058 ( PascalFrancis/Corpus ); précédent : 003057; suivant : 003059De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset
Auteurs : R. K. B. Pearce ; T. Banerji ; P. Jenner ; C. D. MarsdenSource :
- Movement disorders [ 0885-3185 ] ; 1998.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 98-0177441 INIST |
---|---|
ET : | De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset |
AU : | PEARCE (R. K. B.); BANERJI (T.); JENNER (P.); MARSDEN (C. D.) |
AF : | Neurodegenerative Diseases Research Centre, Pharmacology Group, Biomedical Sciences Division, King College/London/Royaume-Uni; National Hospital for Neurology and Neurosurgery/Royaume-Uni |
DT : | Publication en série; Niveau analytique |
SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1998; Vol. 13; No. 2; Pp. 234-241; Bibl. 42 ref. |
LA : | Anglais |
CC : | 002B02U01 |
FD : | Parkinson maladie; Dyskinésie; Lévodopa; Chimiothérapie; Antiparkinsonien; Bromocriptine; Agoniste; Récepteur dopaminergique D2; Ropinirole; De novo; Relation dose réponse; Traitement; Toxicité; Etude comparative; Singe; Animal adulte |
FG : | Primates; Mammalia; Vertebrata; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique; Mouvement involontaire |
ED : | Parkinson disease; Dyskinesia; Levodopa; Chemotherapy; Antiparkinson agent; Bromocriptine; Agonist; D2 Dopamine receptor; Ropinirole; De novo; Dose activity relation; Treatment; Toxicity; Comparative study; Monkey; Adult animal |
EG : | Primates; Mammalia; Vertebrata; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder; Involuntary movement |
GD : | Aufbereiten; Giftigkeit; Vergleich |
SD : | Parkinson enfermedad; Disquinesia; Levodopa; Quimioterapia; Antiparkinsoniano; Bromocriptina; Agonista; Receptor dopaminérgico D2; Ropinirol; De novo; Relación dosis respuesta; Tratamiento; Toxicidad; Estudio comparativo; Mono; Animal adulto |
LO : | INIST-20953.354000079238580060 |
ID : | 98-0177441 |
Links to Exploration step
Pascal:98-0177441Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset</title>
<author><name sortKey="Pearce, R K B" sort="Pearce, R K B" uniqKey="Pearce R" first="R. K. B." last="Pearce">R. K. B. Pearce</name>
<affiliation><inist:fA14 i1="01"><s1>Neurodegenerative Diseases Research Centre, Pharmacology Group, Biomedical Sciences Division, King College</s1>
<s2>London</s2>
<s3>GBR</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>National Hospital for Neurology and Neurosurgery</s1>
<s3>GBR</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Banerji, T" sort="Banerji, T" uniqKey="Banerji T" first="T." last="Banerji">T. Banerji</name>
</author>
<author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">98-0177441</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 98-0177441 INIST</idno>
<idno type="RBID">Pascal:98-0177441</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003058</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset</title>
<author><name sortKey="Pearce, R K B" sort="Pearce, R K B" uniqKey="Pearce R" first="R. K. B." last="Pearce">R. K. B. Pearce</name>
<affiliation><inist:fA14 i1="01"><s1>Neurodegenerative Diseases Research Centre, Pharmacology Group, Biomedical Sciences Division, King College</s1>
<s2>London</s2>
<s3>GBR</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>National Hospital for Neurology and Neurosurgery</s1>
<s3>GBR</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Banerji, T" sort="Banerji, T" uniqKey="Banerji T" first="T." last="Banerji">T. Banerji</name>
</author>
<author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult animal</term>
<term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Bromocriptine</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>D2 Dopamine receptor</term>
<term>De novo</term>
<term>Dose activity relation</term>
<term>Dyskinesia</term>
<term>Levodopa</term>
<term>Monkey</term>
<term>Parkinson disease</term>
<term>Ropinirole</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Bromocriptine</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D2</term>
<term>Ropinirole</term>
<term>De novo</term>
<term>Relation dose réponse</term>
<term>Traitement</term>
<term>Toxicité</term>
<term>Etude comparative</term>
<term>Singe</term>
<term>Animal adulte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>13</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>PEARCE (R. K. B.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BANERJI (T.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>JENNER (P.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MARSDEN (C. D.)</s1>
</fA11>
<fA14 i1="01"><s1>Neurodegenerative Diseases Research Centre, Pharmacology Group, Biomedical Sciences Division, King College</s1>
<s2>London</s2>
<s3>GBR</s3>
</fA14>
<fA14 i1="02"><s1>National Hospital for Neurology and Neurosurgery</s1>
<s3>GBR</s3>
</fA14>
<fA20><s1>234-241</s1>
</fA20>
<fA21><s1>1998</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000079238580060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1998 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>42 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>98-0177441</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Bromocriptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Bromocriptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Bromocriptina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Agonist</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Agonista</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>12</s5>
<s6>«D2» Dopamine receptor</s6>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Ropinirol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>De novo</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>De novo</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>De novo</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Relation dose réponse</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Dose activity relation</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Relación dosis respuesta</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="GER"><s0>Giftigkeit</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="GER"><s0>Vergleich</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Singe</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Monkey</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Mono</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Animal adulte</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Adult animal</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Animal adulto</s0>
<s5>21</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>46</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>47</s5>
</fC07>
<fN21><s1>117</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 98-0177441 INIST</NO>
<ET>De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset</ET>
<AU>PEARCE (R. K. B.); BANERJI (T.); JENNER (P.); MARSDEN (C. D.)</AU>
<AF>Neurodegenerative Diseases Research Centre, Pharmacology Group, Biomedical Sciences Division, King College/London/Royaume-Uni; National Hospital for Neurology and Neurosurgery/Royaume-Uni</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1998; Vol. 13; No. 2; Pp. 234-241; Bibl. 42 ref.</SO>
<LA>Anglais</LA>
<CC>002B02U01</CC>
<FD>Parkinson maladie; Dyskinésie; Lévodopa; Chimiothérapie; Antiparkinsonien; Bromocriptine; Agoniste; Récepteur dopaminergique D2; Ropinirole; De novo; Relation dose réponse; Traitement; Toxicité; Etude comparative; Singe; Animal adulte</FD>
<FG>Primates; Mammalia; Vertebrata; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique; Mouvement involontaire</FG>
<ED>Parkinson disease; Dyskinesia; Levodopa; Chemotherapy; Antiparkinson agent; Bromocriptine; Agonist; D2 Dopamine receptor; Ropinirole; De novo; Dose activity relation; Treatment; Toxicity; Comparative study; Monkey; Adult animal</ED>
<EG>Primates; Mammalia; Vertebrata; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder; Involuntary movement</EG>
<GD>Aufbereiten; Giftigkeit; Vergleich</GD>
<SD>Parkinson enfermedad; Disquinesia; Levodopa; Quimioterapia; Antiparkinsoniano; Bromocriptina; Agonista; Receptor dopaminérgico D2; Ropinirol; De novo; Relación dosis respuesta; Tratamiento; Toxicidad; Estudio comparativo; Mono; Animal adulto</SD>
<LO>INIST-20953.354000079238580060</LO>
<ID>98-0177441</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003058 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003058 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:98-0177441 |texte= De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |